REMOTE PATIENT MONITORING A KEY DRIVER OF GROWTH

Smartphones provide an engine for this change: It is estimated that there will be
2.5 billion smartphones in active use worldwide during 2016.
Health conscious consumers are already embracing self-management and this is evident in the growth of wearable fitness sensors such as Fitbit.

The continued shift toward accountable care will encourage the adoption of remote patient monitors for chronic diseases like asthma, diabetes and cardiovascular illness, with the goal of keeping patients out of the hospital, lowering costs and improving care.

globe

FIRST MOVER ADVANTAGE

Digital Wheeze Detection

  • Our ARM™ technology records airway sounds to detect continuous adventitious breath sounds and measure the extent of wheezing caused by airway obstruction.The measurement is presented as WheezeRATE™, the percentage of time over 30 second recording that wheeze is present
  • Respiri continues to have a first mover advantage with its unique proprietary Acoustic Respiratory Monitoring (ARM™) algorithm technology
  • Respiri devices work like a stethoscope utilising special contact microphones, or acoustic sensors, to pick up breath sounds from the lungs at the windpipe (trachea), and in the clinical devices, the chest
  • Patent portfolio with 73 patents

devices

MULTI-PRODUCT PORTFOLIO

Lowering risk for investors

The company’s portfolio of computerized wheeze detection products is used in both clinical and home monitoring settings.
Our core devices have been cleared by the FDA, TGA and carry the European CE’s mark. AirSonea has been submitted for both FDA and CE clearance as a Class IIa medical device.

MARKET RESEARCH

Respiri has conducted extensive market research I the US and Australia that shows our functional, user friendly product line will meet the expectations of our customer base that includes parents and patients, the medical profession, insurers, pharmacies and other retailers.

Intent to purchase the Airsonea wheeze monitor ranged from 60% to 95% in the various studies.

Key findings:

Parents of children with asthma

  • Parents are constantly worrying about their child’s health and wondering when the next attack will occur and what will trigger it
  • They admit they could be more diligent and none feel like they are in complete control
  • ‘Asthma guilt’ is pervasive. It’s a function of the pressure of day-to-day life overwhelming the best of intentions; coupled with more ‘reactive’ approach to an asthma attack rather than ‘proactive’ management
  • They also find it difficult to articulate the severity of symptoms to doctors, a source of some frustration

Adults with asthma

  • Adults with asthma (secondary market) have more established knowledge of their asthma and “know if I’m wheezing or not”. Certainly interested, but not to the same degree as parents

Key findings:

Medical professionals

In addition to consumer research, Respiri also conducted qualitative in-depth iterviews with key asthma experts and a quantitative study with a total of 100 Australian GPs including 50 paediatricians who routinely treat asthma.

  • Results found that 80% of GPs and 62% of paediatricians in the study would recommend Respiri’s new mobile wheeze monitoring system to their asthma patients.
  • In general, the product was perceived as an important management tool for patients who would benefit from more frequent home monitoring or asthma symptoms, which were characterised as 75% of patients with unstable asthma and approximately half of all patients with stable asthma.

Physicians considered home monitoring of asthma “very important”, chiefly to assist in the management of asthma treatment plans and ensuring medication adherence. They noted historically, the use of peak flow meters and diaries has been met with poor compliance and reliability.

primary-market